Industry: Cannabis and psychedelics
Cannabis and psychedelics funding
Psychedelic drug developers can tap biotech investors and drugmakers, but licensed cannabis firms still struggle to find and keep a bank. We show investors and lenders how the rules in each market shape your numbers.
- Rules for each market, checked on official pages and dated
- Decks, models and lender packs for plant-medicine companies
- Waveup prepares investor materials for cannabis and psychedelics companies: $3B+ raised for 600+ startups since 2014
In short
What is cannabis and psychedelics funding?
Cannabis and psychedelics funding is the money plant-medicine companies raise: equity, loans, grants and sale proceeds. Psychedelic drug developers raise much like biotechs. State-licensed cannabis businesses have a harder time, because federal law still keeps most banks away. In 2024, only about 1,000 US banks and credit unions reported serving them.
- Who it's for
- Cannabis operators and brands, psychedelic drug developers and clinics, pre-seed to Series D+
- What we build
- Investor deck, financial model, lender materials, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Can cannabis and psychedelic companies still raise money in 2026?
Yes, but each market draws on different money. Drug developers attract biotech investors and drugmakers, while licensed cannabis operators lean on private lenders.
The opportunity
Federal rules began to move in 2026, and drugmakers are now paying for psychedelic drugs.
- The DEA opened a hearing on 29 June 2026 on moving all marijuana to Schedule III; no decision yet
- Lilly closed its purchase of psychedelic drug developer AtaiBeckley in September 2026
- The SAFE Banking Act, which would shield banks that serve cannabis, returned to Congress in June 2026
The problem
Most US banks still keep away from state-licensed cannabis. Two major card networks, Visa and Mastercard, also bar cannabis purchases.
Market size
How big are these markets, and which rules move them?
The US had 21,760 licensed cannabis businesses at the end of 2025. Three years earlier there were 27,852. Psychedelic medicine is still in trials, so investors value it on data and deals. Four rule changes shape where money goes next:
- Schedules: since 28 April 2026, state-licensed medical marijuana is Schedule III, while adult-use is still Schedule I
- Hemp: after one delay, many hemp THC products stop counting as hemp under federal law from 11 December 2026
- Germany: imports of medical cannabis flowers reached 201.1 tonnes in 2025
- Psychedelics: an April 2026 executive order called for a Right to Try route to experimental psychedelics, ibogaine included
Venture capital
Where does the money for cannabis and psychedelic companies come from?
Psychedelic drug developers raise as biotechs do: venture rounds, stock listings and sales to drugmakers. Licensed cannabis businesses rely more on private lenders and on investors they already know.
of insured US banks and credit unions reported serving cannabis businesses in 2024
interest on loans offered to cannabis owners, as reported in GAO focus groups
cannabis owners who sought government grants or loans got them, GAO found
Who invests in cannabis and psychedelic companies?
Funds that back both markets are rare, so most companies mix investors, specialist banks and buyers. A few names by type. For psychedelic VCs, see our top VCs investing in psychedelic startups.
Investor database
Pharma investors in our database
The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by pharma investments
Investments by industry
- Healthtech & Wellness42%
- Pharma19%
- Biotech17%
- Rounds
- Pre-seedSeed
- Average cheque
- Not listed
- Based in
- Los Angeles, California, United States
28 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness40%
- Software & Apps15%
- Pharma7%
- Rounds
- Pre-seedSeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Dallas, United States
- Invests in
- USA
88 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness49%
- Biotech20%
- Pharma14%
- Rounds
- SeedSeries A
- Average cheque
- Not listed
- Based in
- Toronto, Ontario, Canada
25 investments in total, 5 tagged Pharma.Open the full fund profile
Investments by industry
- Biotech21%
- Healthtech & Wellness19%
- Hardware. Robotics & IoT17%
- Pharma7%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $1M–$3M$3M–$10M
- Based in
- Jackson, United States
- Invests in
- USA
62 investments in total, 3 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness50%
- Biotech19%
- Pharma6%
- Rounds
- Seed
- Average cheque
- Not listed
- Based in
- San Francisco, United States
- Invests in
- Europe, USA, Canada
33 investments in total, 2 tagged Pharma.Open the full fund profile
From our investor database.
Which rules trip up cannabis and psychedelic raises?
We asked 56 VCs why they pass in our Fundraising 2025 study. Revenue growth, unit economics, burn and missed milestones topped the list. Defensibility and crowded categories came next. In plant medicine, the rules add four questions of their own.
Costly loans and control terms
Cannabis owners in all eight GAO focus groups were offered loans with high fees or rates. A few met investors whose contracts could hand them control.
What investors ask
- Who funds you if banks say no, and on what terms?
What your deck shows
- Your capital stack: each source, its cost and its rights
- A raise plan that keeps control with the founders
Bank fees and closed accounts
Some cannabis owners told the GAO they pay $100,000 or more a year in bank fees. Others saw accounts closed with little warning.
What investors ask
- What happens to payroll and suppliers if your bank drops you?
What your deck shows
- A second banking partner, and what each one costs
- Banking costs shown in the model, not buried in overheads
Sales that rest on one country's rules
Since 29 July 2026, Germany's public health insurance no longer pays for cannabis flowers. Extracts and approved cannabinoid drugs are still covered.
What investors ask
- How much of your revenue depends on one country's rules?
What your deck shows
- Sales by country and by who pays
- How fast you could move supply to another market
Prices that wait on the DEA
Part of Lilly's payment for AtaiBeckley comes only after FDA approval and DEA rescheduling. For one drug, Lilly set a seven-year deadline.
What investors ask
- Which rule change does your valuation assume, and by when?
What your deck shows
- Your value with and without rescheduling
- Payments tied to each regulatory step
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Your licences, rules and numbers, told as one clear story.
Cash flow under each rule scenario, from tax to rescheduling.
A range that shows what rescheduling would and wouldn't change.
Funds, lenders and buyers that already work with plant medicine.
Licences, compliance records and contracts, filed for diligence.
For a sale to a consolidator, a drugmaker or another buyer.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.
About usCannabis and psychedelics funding FAQ
How do cannabis and psychedelic companies raise money?
Why won't banks work with cannabis businesses?
Does moving cannabis to Schedule III fix banking?
What is the SAFE Banking Act, and has it passed?
Do psychedelic companies face the same banking problems as cannabis?
How much does help with a cannabis or psychedelics raise cost?
Industries we work with
Cannabis & Psychedelics
- Cannabis & Psychedelics
- Cannabis
- Cannabis Biotech
- Cannabis Products
- Cannabis Wellness
- Psychedelics
Raising for a cannabis or psychedelics company?
Tell us your licences, your markets and how much you need. We'll show you what investors and lenders will check first.





